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Alzheimer’s diseaseDisruption of beta-amyloid (Ab) transport across the blood–brain barrier is thought to cause Ab
accumulation in the brain, thus leading to the development of Alzheimer’s disease (AD). As AD
patients show increased serum tumor necrosis factor-a (TNFa) levels, we examined the effect of
TNFa on the function and expression of Ab transport-related proteins including cellular prion
protein (PrPC) in the mouse brain microvascular endothelial cell line MBEC4. TNFa decreased PrPC
levels and intracellular radiolabeled Ab. Similarly, anti-prion protein antibody also decreased
radiolabeled Ab. These results suggest that TNFa lowers PrPC levels, which in turn, reduces Ab in
the brain endothelium.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The blood–brain barrier (BBB) serves as an interface between
blood and cerebral interstitial ﬂuid and plays a key role in main-
taining brain homeostasis. Beta-amyloid (Ab) is thought to accu-
mulate in the brain of Alzheimer’s disease (AD) patients, in part,
as a result of an increased net inﬂux of the protein into the brain.
This occurs because of an increased inﬂux, or decreased efﬂux of
Ab through the BBB. There are several Ab transporters found on
brain microvascular endothelial cells, such as P-glycoprotein
(P-gp), low density lipoprotein receptor-related protein 1 (LRP1),
and cellular prion protein (PrPC). Brain endothelial Ab transporta-
tion is regulated by an efﬂux through P-gp and an inﬂux through
LRP1 and PrPC [1–4]. However, the molecular mechanisms explain-
ing how these Ab transporters are regulated remains unclear.Serum levels of tumor necrosis factor-a (TNFa) are increased in
AD patients compared to age-matched healthy controls [5].
Anti-TNFa therapy reduces TNFa levels and Ab plaques in an AD
transgenic mouse model [6], and improves cognitive function of
AD patients [7]. Therefore, it is possible that TNFa affects the
dynamic state of Ab, speciﬁcally, the accumulation or elimination
of Ab from the brain. TNFa is reported to increase P-gp expression
in brain endothelial cells [8]. Whether TNFa-induced P-gp expres-
sion regulates Ab transportation in brain microvascular endothelial
cells has not been reported. Furthermore, the effect of TNFa on the
expression of the other Ab transporters, LRP1 and PrPC, is not
known. In an effort to understand the role of TNFa in the
pathophysiology of AD, we examined whether TNFa regulates Ab
transportation. Additionally, we examined the expression levels
of P-gp, PrPC and LRP1 in the immortalized mouse brain microvas-
cular endothelial cell line MBEC4.
2. Materials and methods
2.1. Peptides and antibodies
Recombinant mouse TNFa was purchased from R&D Systems
(Minneapolis, MN). Synthetic Ab42 peptide was purchased from
Peptide Institute, Inc. (Osaka, Japan). Anti-LRP1 antibody and
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UK). Anti-P-gp antibody was purchased from Calbiochem (San
Diego, CA). Anti-prion protein (SAF32) antibody was purchased
from Bertin Pharma (Montigny-le-Bretonneux, France). HRP-
conjugated anti-mouse and anti-rabbit IgG secondary antibodies
were purchased from GE Healthcare (Waukesha, WI). Calcein-AM
was purchased from Mo Bi Tec (Goettingen, Germany).
2.2. Cell culture
Isolation of mouse brain endothelial cell line, MBEC4, was
described previously [9]. Cells were cultured in Dulbecco’s Modi-
ﬁed Eagle Medium (Wako, Osaka, Japan) supplemented with 10%
fetal bovine serum and penicillin and streptomycin at 37 C in a
humidiﬁed atmosphere of 5% CO2/95% air.
2.3. Uptake assay of 125I-Ab
A stock solution (Stock 1) of Ab42 was prepared by dissolving
lyophilized Ab42 peptide in 1,1,1,3,3,3-hexaaﬂuoro-2-propanol
(HFIP; Sigma–Aldrich, St. Louis, MO) to a ﬁnal concentration of
1 mg/ml. After shaking for 1 h at 4 C, the Stock 1 solution was
aliquoted into tubes. Aliquots were further dissolved in HFIP to
a ﬁnal concentration of 5 lg/tube (Stock 2). Stock 2 was aliquoted
into tubes, dried and stored at 20 C. Just prior to each experi-
ment, Ab42 Stock 2 was dissolved in dimethyl sulfoxide. 125I
radionuclide was purchased from PerkinElmer (Waltham, MA).
Proteins were labeled with 125I using IODO-BEADS Iodination
Reagent (PIERCE, Rockford, IL) following the manufacturer’s
instructions. 125I-Ab42 was puriﬁed using a column ﬁlled Sepha-
dex G-10 (Sigma–Aldrich).
MBEC4 cells were cultured in 12-well plates and grown to
90–100% conﬂuence. Prior to experiments, cells were washed three
times with ECF buffer (138 mM NaCl, 5.0 mM KCl, 1.3 mM CaCl2,
0.8 mM MgCl2, 0.3 mM KH2PO4, 0.3 mM Na2HPO4, 5.6 mM D-glu-
cose, 10 mM HEPES, pH 7.4) and incubated at 37 C with ECF buffer
containing 125I-Ab42 (incubation buffer) for 60 min. Verapamil was
added simultaneously. SAF32 was added 30 min before 125I-Ab42
treatment. The incubation buffer was removed and cells were
washed ﬁve times with ice-cold ECF buffer and two times with acid
wash buffer (28 mM CH3COONa, 120 mM NaCl, 20 mM sodium
barbital, pH3.0). Cells were lysed using 1% Triton-X-100. Cell
lysates or incubation buffer was mixed with trichloroacetic acid
(ﬁnal concentration, 10%) and bovine serum albumin (ﬁnal concen-
tration, 0.33%) and centrifuged at 2380g for 10 min. The precipi-
tates were quantitated using a c counter. Cellular protein was
measured using the BCA Protein Assay Reagent kit (Thermo scien-
tiﬁc, Waltham, MA). Intracellular 125I-Ab42 was expressed as the
cell/medium ration (see below). The cell/medium ratio (ll/mg of
protein) is equal to 125I counts in the cells (cpm/mg protein)/125I
counts in the incubation buffer (cpm/ll).
2.4. Calcein-AM efﬂux assay
The functional activity of P-gp was determined by measuring
the cellular accumulation of calcein according to Ott et al. (2010)
[10]. Calcein-AM converts to calcein, which is a P-gp substrate
and a ﬂuorescent substance when taken up by cells. Cells cultured
in 12-well plates were grown to 90–100% conﬂuence. Cells were
washed three times with Krebs–Ringer buffer (KRB; 118 mM NaCl,
4.7 mM KCl, 1.3 mM CaCl2, 1.2 mM MgCl2, 1.0 mM NaH2PO4,
25 mM NaHCO3, and 11 mM d-glucose, pH 7.4) and loaded with
KRB containing 1 lM calcein-AM for 30 min at 37 C. Verapamil
was treated simultaneously. Cells were then washed three times
with ice-cold KRB and lysed with 1% Triton X-100. The concentra-
tion of calcein was determined using a ﬂuorescence multiwellplate reader (Ex(k) 485 nm; Em(k) 530 nm; CytoFluor Series
4000). Cellular protein was measured using the BCA Protein Assay
Reagent kit.
2.5. WST8 assay
For evaluation of cell proliferation and survival rate, Cell
Counting Kit-8 (Dojindo, Kumamoto, Japan) was used following
the manufacturer’s instructions.
2.6. Immunoblot analysis
Cell lysates were separated by SDS–PAGE and then transferred
to PVDF membranes. The membranes were blocked with the
blocking reagent Blocking One (Nacalai Tesque, Kyoto, Japan),
and incubated with primary antibody (for P-gp, PrPC or LRP1)
and the appropriate secondary antibody. The membranes were
visualized using an ECL Advance Western Blotting Detection kit
(GE Healthcare) and analyzed using a FluorChem™ imaging system
(Alpha Innotech, Santa Clara, CA, USA).
2.7. Quantitative RT-PCR
Following TNFa treatment, total RNA was extracted from cells
using the QIAshredder™ and RNeasy mini kit (Qiagen, Hilden,
Germany). First-strand cDNA was reverse-transcribed from total
RNA using a SuperScript VILO™ cDNA Synthesis kit (Invitrogen,
Carlsbad, CA). Real-time PCR was conducted on an Mx3000P™
Multiplex Quantitative PCR System (Stratagene, La Jolla, CA) using
SYBR Green Real-time PCR Master Mix Plus (Toyobo, Osaka, Japan)
and primers per the manufacturer’s protocol. The following PCR
conditions were employed: 95 C for 15 s, 60 C (for PrP, Mdr1a
and Mdr1b) or 54 C (for GAPDH) for 30 s and 72 C for 45 s. The pri-
mer sequences were as follows: 50-CTGCTGGCCCTCTTTGTGAC-30
and 50-CTTTTTGCAGAGGCCGACAT-30 for PrP; 50- CATGACAGATA
GCTTTGCAAGTGTAG-30 and 50- GGCAAACATGGCTCTTTTATCG-30
for Mdr1a, 50- AAGCCAGTATTCTGCCAAGCAT-30 and 50- CTCCAGA
CTGCTGTTGCTGATG-30 for Mdr1b, 50-AACTTTGGCATTGTGGAAGG-
30 and 50-GGATGCAGGGATGTTCT-30 for GAPDH. Relative quantita-
tive analysis was performed using Mx3000P™ Multiplex Quantita-
tive PCR software (Stratagene) and the levels of PrP, Mdr1a and
Mdr1b were compared with those of GAPDH.
2.8. Statistical analysis
Data were evaluated for statistical signiﬁcance using a one-way
analysis of variance followed by Tukey’s multiple comparison test
or Dunnett’s multiple comparison test, except for comparisons of
two means. When only two means were compared, the statistical
signiﬁcance of the difference was determined by unpaired t test.
The criterion for statistical signiﬁcance was P < 0.05. Data are pre-
sented as means ± standard error (SE).3. Results
To examine the effect of TNFa on Ab uptake in MBEC4 cells,
cells were treated with TNFa for 24 h, followed by exposure to
125I-Ab42. TNFa reduced intracellular accumulation of 125I-Ab42
in by 10 to 20% dose-dependently (Fig. 1A). TNFa did not affect cell
proliferation or survival rate (Fig. 1B). These results suggest that
reduced levels of the intracellular 125I-Ab42 occur due to either
increased Ab elimination from cells or decreased Ab uptake into
cells.
To determine whether TNFa-reduced intracellular 125I-Ab42
levels are due to increased Ab elimination from cells, the effect of
A B
Fig. 1. (A) TNFa-induced reduction in intracellular 125I-Ab levels in MBEC4 cells. Cells were treated with TNFa (0.1–2.0 ng/ml) for 24 h and incubated with 125I-Ab for 60 min
(n = 14–21). (B) Cell proliferation and survival rates in TNFa-treated MBEC4 cells. MBEC4 cells were treated with TNFa (0.1–2.0 ng/ml) for 24 h and incubated with WST8 for
60 min (n = 6). The data are expressed as percentages of control values (NT: non-treatment). Each bar indicates the mean ± SE, ⁄P < 0.05, ⁄⁄⁄P < 0.001, signiﬁcantly different
from NT.
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MBEC4 cells. Cells were treated with TNFa (0.1–2.0 ng/mL) for
24 h. This resulted in a dose-dependent increase in P-gp expression
(Fig. 2A). P-gp is encoded by the multidrug resistance (MDR) gene
family which includes; mdr1a, mdr1b, and mdr2. Mdr1a and mdr1b
express multidrug efﬂux transporters [11], while mdr2 expresses
phospholipid transporters [12,13]. Therefore, a time-course for
mdr1a and mdr1b mRNA levels was examined following TNFa
treatment in MBEC4 cells (Fig. 2B and C). The level ofMdr1bmRNA
expression increased in a time-dependent manner, and this
increase (61%) was signiﬁcant 3 h after treatment. Additionally, a
further increase inMdr1b expression was observed 18 h after TNFa
treatment (107%) (Fig. 2C). Mdr1a mRNA levels were analyzed for
up to 18 h following TNFa treatment and no increase was observed
(Fig. 2B). To examine the functional activity of P-gp, calcein trans-
portation was analyzed [10]. Verapamil (100 lM), a P-gp blocker,
increased intracellular calcein accumulation in the absence of
TNFa in MBEC4 cells (Fig. 2D). TNFa treatment signiﬁcantly
reduced intracellular calcein accumulation by 12%, whereas,
verapamil completely blocked the effect of TNFa (Fig. 2D). Regard-
ing Ab42 transportation, verapamil also increased intracellular
125I-Ab42 accumulation in the absence of TNFa. TNFa treatment
signiﬁcantly reduced 125I-Ab42 accumulation by 14% in the
absence of verapamil (Fig. 2E), similar to results shown in
Fig. 1A. Decreased 125I-Ab42 accumulation in response to TNFa
was not completely blocked by verapamil, and lowered 125I-Ab42
remained signiﬁcant (11%) after verapamil treatment (Fig. 2E). This
suggests the involvement of a mechanism separate from P-gp.
LRP1 and PrPC have been reported to mediate Ab endocytosis in
brain endothelial cells [3,4]. Thus, we examined the expression lev-
els of LRP1 and PrPC in TNFa-treated MBEC4 cells. TNFa dose-
dependently decreased PrPC protein levels by 13–40%, but did
not effect the levels of LRP1 in these cells (Fig. 3A and B). PrPmRNA
expression levels were tested for up to 18 h following TNFa treat-
ment and a time-dependent decrease was observed (Fig. 3C). These
ﬁndings suggest that TNFa decreases the synthesis, rather than
increasing degradation of PrPC. Furthermore, decreased PrPC
expression is associated with reduced intracellular 125I-Ab42 accu-
mulation. To test whether PrPC mediates Ab endocytosis in MBEC4
cells, we examined the effect of the anti-prion protein antibody on
intracellular 125I-Ab42 levels. Pre-treatment with the anti-prion
protein antibody (SAF32) signiﬁcantly decreased intracellular
125I-Ab42 accumulation by 11% (Fig. 3D).4. Discussion
In the present study, TNFa increased P-gp and decreased PrPC
expression levels, but did not change LRP1 levels in MBEC4 cells.
Furthermore, TNFa decreased intracellular 125I-Ab42 accumulation
in MBEC4 cells. Verapamil, a P-gp blocker, did not completely
restore TNFa-induced reduction of 125I-Ab42 levels in these cells.
Brain endothelial 125I-Ab42 accumulation was reduced following
treatment with an antibody targeting PrPC. These results suggest
that TNFa inhibits Ab uptake by downregulating PrPC expression
and promotes Ab efﬂux by upregulating P-gp expression in brain
endothelial cells. Given that verapamil incompletely blocks
reduced Ab accumulation in response to TNFa, we propose that
the downregulation of PrPC is likely the predominant factor for this
phenomenon. We hypothesize that TNFa-increased P-gp expres-
sion and function is not effective in eliminating Ab from endothe-
lial cells because intracellular Ab levels are lowered due to
TNFa-decreased PrPC expression and function for Ab uptake into
cells. This process likely contributes to increased Ab accumulation
in the AD brain.
PrPC positively regulates Ab transportation in brain endothelial
cells [4]. Therefore, decreased PrPC in brain endothelial cells is
thought to disrupt Ab efﬂux from the brain parenchyma to the
blood leading to increased Ab accumulation in the brain, AD
patients show reduced PrPC levels in their cerebrospinal ﬂuid
[14]. However, PrPC levels have not yet been evaluated in the brain
endothelial cells of AD patients. Our study demonstrates that
TNFa, which expression is increased in AD patients, reduces PrPC
levels and disrupts Ab transportation in brain endothelial cells.
Therefore, it is likely that activation of TNFa signaling at the BBB
is closely associated with reduced PrPC levels in the cerebrospinal
ﬂuid of AD patients.
PrPC synthesis is mediated by the transcriptional activator SP-1,
metal transcriptional factor-1 (MTF-1), AP-1, and the transcrip-
tional repressor, Hes1 [15–17]. We examined changes in the phos-
phorylation level of SP-1 in MBEC4 cells and found that there were
no differences between TNFa treatment and controls. In addition,
contrary to our expectation, the expression of c-Jun (which is con-
stituent element of AP-1) is increased and Hes1 mRNA levels are
decreased in TNFa-treated cells (data not shown). In the present
study, we could not identify downstream molecules that regulate
PrPC expression in the TNFa signaling pathway. This is now being
further investigated.
AB C
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Fig. 2. (A) TNFa-induced dose-dependent increase in P-gp levels in MBEC4 cells. P-gp expression was examined 24 h after TNFa treatment (0.1–2.0 ng/ml, n = 12 each). The
data are expressed as percentages of control values (NT). Each bar indicates the mean ± SE, ⁄P < 0.05, ⁄⁄P < 0.01, signiﬁcantly different from NT. Representative immunoblots
(top) and densitometric analysis (bottom) of P-gp and b-actin levels. (B and C) Time-course of TNFa-induced changes in mdr1a and mdr1b mRNA levels, respectively, in
MBEC4 cells. These were measured 3 and 18 h after treatment with TNFa (2 ng/ml) by real-time RT-PCR (n = 6 each). Mdr1a and mdr1b mRNA levels were normalized to
GAPDHmRNA levels. Values are means ± SE, ⁄P < 0.05, ⁄⁄P < 0.01, signiﬁcantly different from 0 h (just before treatment). (D) TNFa-induced changes in the intracellular calcein
levels in MBEC4 cells treated without or with verapamil. Cells were treated with TNFa (2 ng/ml) for 24 h and then incubated with calcein-AM in the absence or presence of
verapamil (100 lM) for 30 min (n = 4). The data are expressed as percentages of control values (NT without verapamil). Each bar indicates the mean ± SE, ⁄⁄⁄P < 0.001,
signiﬁcantly different. n.s.: no signiﬁcance (E) TNFa-induced changes in the intracellular 125I-Ab accumulation in MBEC4 cells treated without or with verapamil. Cells were
treated with TNFa (2 ng/ml) for 24 h and then incubated with 125I-Ab in the absence or presence of verapamil (100 lM) for 60 min (n = 18). The data are expressed as
percentages of control values (NT without verapamil). Each bar indicates the mean ± SE, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001, signiﬁcantly different.
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in MBEC4 cells are increased in response to TNFa. This suggests
that P-gp encoded by mdr1b rather than mdr1a could contribute
to Ab transportation in brain endothelial cells. Mdr1a and mdr1b
express distinct P-gp subtypes possessing different drug speciﬁci-
ties. Mdr1b encodes P-gp with preferential resistance to colchicine
and adriamycin, while mdr1a encodes P-gp with preferential resis-
tance to actinomycin D [11]. Whether Ab is a speciﬁc substrate for
P-gp expressed by mdr1a or mdr1b has not yet been shown. Vita-
min D receptor ligand increases mdr1b, but not mdr1a mRNA
expression, and promotes Ab efﬂux from brain endothelial cells[18]. Taken together, it is conceivable that mdr1b is more sensitive
to speciﬁc ligands or conditions compared to mdr1a. Mdr1b may
underlie the primary role of P-gp expression in response to various
pathophysiological conditions including TNFa-mediated brain
inﬂammation.
In conclusion, we present the ﬁrst evidence that suggests that
TNFa-induced disruption of Ab transportation at the BBB contrib-
utes to AD. We show that TNFa inhibits Ab uptake and promotes
Ab efﬂux due to decreased PrPC and increased P-gp expression in
brain microvascular endothelial cells. Lowered Ab uptake predom-
inantly contributes to an acceleration of Ab accumulation in brain
Fig. 3. TNFa-induced changes in PrPC (A) and LRP1 (B) expression in MBEC4 cells. Protein expression was examined 24 h after TNFa treatment (0.1–2.0 ng/ml, n = 12 each).
The data are expressed as percentages of control values (NT). Each bar indicates the mean ± SE, ⁄⁄⁄P < 0.001, signiﬁcantly different from NT. Representative immunoblots (top)
and densitometric analysis (bottom) of PrPC, LRP1 and b-actin levels. (C) TNFa-induced a time-dependent decrease in PrPC mRNA levels in MBEC4 cells. mRNA expression was
measured by real-time RT-PCR 3 and 18 h after treatment with TNFa (2 ng/ml) (n = 6). PrPC mRNA levels were normalized to GAPDH. Values are means ± SE, ⁄P < 0.05,
signiﬁcantly different from 0 h (just before treatment). (D) Anti-prion protein antibody-induced reduction of intracellular 125I-Ab accumulation in MBEC4 cells. Cells were
treated with anti-prion protein antibody (SAF32, 1 lg/ml) for 30 min and then incubated with 125I-Ab for 60 min (n = 9). The data are expressed as percentages of control
values (NT). Each bar indicates the mean ± SE, ⁄⁄P < 0.01, signiﬁcantly different from NT.
Y. Yasutaka et al. / FEBS Letters 589 (2015) 263–268 267parenchyma. Thus, our ﬁndings indicate the possible involvement
of PrPC in AD pathophysiology and that anti-TNFa therapy could be
a useful strategy to prevent disruption of Ab transportation across
the BBB.
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